Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Advanced Gastric Cancer 1

Interventions

Carboplatin 7Paclitaxel 6Talc 5Docetaxel 5Bevacizumab 4Taxes 3Gemcitabine 3Cisplatin 3Trastuzumab 2High-Energy Shock Waves 2Erlotinib Hydrochloride 2Doxycycline 2Cetuximab 2Bortezomib 2viscum album peptide 1tipifarnib 1saracatinib 1romidepsin 1endostar protein 1Zoledronic Acid 1Vinorelbine 1Valacyclovir 1Tyrosine Kinase Inhibitors 1Thoracoscopy 1Thoracoscopes 1Thoracic Surgery, Video-Assisted 1Thoracentesis 1Surveys and Questionnaires 1Sorafenib 1Povidone-Iodine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pleural Effusion, Malignant × endostar protein × Clear all
NCT01327235 2014-08-01

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
336 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡